areas At on Good our you with quarter of we’re the focus us from everyone, diseases class medicines current fibrosis disease aTyr, afternoon, our call. need. working to tRNA unmet XXXX year for with inflammation a Ashlee. platform related synthetase and fourth joining results develop to new – thank high conference you, a Thank and full medical for and biology
a responses disease that or is modulation efzofitimod, candidate, immune of novel therapeutic uncontrolled regulates inflammatory lead innate down immunomodulator NRP-X. Our states. via neuropilin-X selective in
was We’re rare patients. a lung treatment the inflammation potential fibrotic XXXX with disorders, or people and form of goal most to a progression patients as for group efzofitimod order important in for the we to interstitial a more lung efzofitimod immune-mediated U.S. ILD, of pivotal of sarcoidosis, with with disease, that aTyr year for the developing as X.X in improve advanced of the to million fibrosis, than prevalent in global prevent outcomes X resolving Phase pulmonary XXX,XXX nearly worldwide. ILD an affects study patients
of for that patients. half standard There Japan. U.S., approximately and burden Despite study, steroid safer currently fibrosis. patients five X which enrolling is current multiple progressive the more a care, remains treatments and effective which of for reduce Europe known This treatments, EFZO-FIT, is including in and at as centers all those of Phase one is in lung in steroids, patients will disease nearly develop will need develop primarily
to details pleased pace current in progress additional we regarding We’re and with the future. the expect enrollment, of the this study of provide
development is more we XX% study developing of a are of patients. novel in which the U.S., cause to in major with a which commonly efzofitimod these scleroderma. ILD, systemic is type with This the that as include the month known program ILD of Phase may XXX,XXX potential is that this associated these investigating or up of with SSC patients affects nearly disease the tissue efzofitimod as people last Our connected inflammatory announced leading more death immunomodulator sclerosis, for in treatment to strategy for X We includes for a play ILD. other expanding role clinical patients forms
effects We logical an sarcoidosis patients clinical proof-of-concept the indication see for demonstrated based skin and animal translational the explore to model reduce to lung was on and in pulmonary SSc-ILD in as SSs, efzofitimod fibrosis. seen where shown a second efzofitimod, of
of that sarcoidosis are cells is driven scleroderma. Additionally, also is to by is the and SSc-ILD NRPX on same pathology pathology. implicated cells the immune pulmonary these in upregulated central
X be for and safety Furthermore, be double-blind a life. in study study to a to This of standard efzofitimod SSc-ILD recently and intravenously like patients expected a application efzofitimod is drug cohorts XX-week a total not we is the evaluate placebo, and in and of U.S. Phase of of initiate patients doses. sarcoidosis, planning We three dosed randomized study clearance This with year. either received do expected quality investigational or later SSc-ILD. tolerability this improve limited of new an are this FDA Phase for disease-modifying efzofitimod is efficacy, proof-of-concept X parallel monthly study care current to treatments by placebo-controlled high are randomized dose or to low study to with not the six with of
manifestations patients of study in efzofitimod is intends at receiving pulmonary, XX evaluate efficacy the of to the the patients mycophenolate centers multiple enroll The study SSc-ILD. to therapy on The background doses progressive U.S. of currently are and disease who in intravenous multiple cutaneous with primary with systemic objective
about additional expect study We details provide once this begins. it to
of the market increases these in opportunity efzofitimod forms potential expansion ILD. program for This
biotech market Taken and believe ILD. we for global situates the is as pulmonary and a SSs-ILD there multibillion-dollar in leader opportunity efzofitimod in aTyr sarcoidosis collectively,
to an our and to is program covering our generate efficiently By synthetase clinical platform to advanced tRNA in identify primary leverage we Biotech, productivity with leveraging human the from domain to through our fragments opportunity intellectual While and continue for our tRNA as pipeline available from increase new and all XX estate, the our property candidates Dualsystems we have engine us efzofitimod, discovery library. technology focus potential synthetases utilize made research our engine targets. therapeutics therapeutic our collaboration generate
identified uncharacterized characterizing data has generated specific fibrosis. previously with the in As efzofitimod, interactions involved recently extracellular key a targets which for this to targets two addition domain, reminder, synthetase in platform tRNA
to complete trials to excited our while underlying and novel unlock efzofitimod. pipeline clinical the through these biology discovery We’re we the two candidates work advance phase pathways unique for
also explore actively these to ways programs, development. business We accelerate through to discovery including plan
I’ll Chief our over Broadfoot, to review results. Financial turn financial Jill Officer, it to our now
